Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
Vanda Pharmaceuticals announced that Japan's Ministry of Health, Labour and Welfare granted orphan drug designation to imsidolimab for generalized pustular psoriasis (GPP). The designation unlocks development incentives in Japan, including R&D subsidies and the potential for up to 10 years of market exclusivity following approval.
Key figures
- Drug Name
- imsidolimab
- Japan gpp patients
- 2200
- Market exclusivity years
- 10
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.